The Manufacturers Life Insurance Company Sells 7,162 Shares of Repligen Corporation $RGEN

Posted by Brian Himes on Aug 6th, 2026

The Manufacturers Life Insurance Company lowered its stake in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) by 12.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 49,940 shares of the biotechnology company’s stock after selling 7,162 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Repligen were worth $5,884,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of RGEN. Measured Wealth Private Client Group LLC purchased a new stake in Repligen in the third quarter worth about $29,000. Bayforest Capital Ltd bought a new stake in Repligen during the 4th quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC purchased a new position in shares of Repligen during the 4th quarter worth approximately $33,000. Los Angeles Capital Management LLC bought a new position in shares of Repligen in the 4th quarter worth approximately $36,000. Finally, Farther Finance Advisors LLC raised its position in shares of Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 128 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Insider Buying and Selling at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Evercore restated an “outperform” rating and issued a $160.00 target price on shares of Repligen in a research note on Monday, July 6th. Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, July 14th. Citigroup raised Repligen to a “buy” rating in a research report on Tuesday, July 7th. Barclays boosted their target price on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, Wells Fargo & Company upped their target price on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $166.43.

Read Our Latest Stock Analysis on RGEN

Repligen Stock Performance

Shares of RGEN opened at $158.59 on Thursday. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.95 billion, a P/E ratio of 217.25, a P/E/G ratio of 2.73 and a beta of 1.03. The business’s 50 day moving average price is $136.90 and its 200-day moving average price is $131.09. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77.

Repligen (NASDAQ:RGEN – Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities research analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Repligen Profile

(Free Report)

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.